Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394210 | 0.85 | PDE10A (0.56) | KDM4EALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL20406776 | 0.81 | KMT2A (0.56) | KDM4EALDH1A1PDE10ABTKPOLB | |
| SCHEMBL20406368 | 0.81 | PDE10A (0.46) | KDM4EPDE10ABTK | |
| SCHEMBL20406242 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2LMNACYP2A6 | |
| SCHEMBL20406392 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2LMNAPDE10A | |
| SCHEMBL20754916 | 0.78 | PDE10A (0.49) | PDE10ABTK | |
| SCHEMBL20394162 | 0.78 | PDE10A (0.49) | ALDH1A1PDE10ABTKTDP1 | |
| SCHEMBL20394208 | 0.78 | PDE10A (0.49) | PDE10A | |
| SCHEMBL367302 | 0.77 | BTK (0.45) | ALDH1A1BTKPOLB | |
| SCHEMBL20406269 | 0.77 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2LMNAPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | KDM4E 2642/4885ALDH1A1 2994/4885SMN1; SMN2 4801/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | KDM4E 2642/4885ALDH1A1 2994/4885SMN1; SMN2 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.